Blood Tests Track Cervical Cancer Return After Surgery or Treatment
Tests blood DNA monitoring to predict cervical cancer recurrence in adults after treatment.
Plain-language title generated from the registry record
Registry title: Dynamic Monitoring of ctDNA and HPV DNA in Plasma for the Early Prediction of Recurrence After Cervical Cancer Surgery
Key facts
- Where
- Guangzhou, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adult women newly diagnosed with HPV-positive cervical cancer who have not yet had surgery, radiation or chemotherapy. Blood tests will track tumor DNA and HPV DNA after treatment.
- Age
- Older than 18 years
- Sex
- Women only
- Disease stage
- Newly diagnosed HPV-positive cervical cancer, stages I-IV, able to have surgery and/or chemoradiotherapy
- Earlier treatment
- No surgery, radiation therapy or chemotherapy before joining
- Biomarker or test result
- HPV-positive cervical cancer
Main reasons for not taking part
- Taking part in other clinical trials
- Pregnant or breastfeeding
- Severe mental illness
- Unable to complete the study protocol
Read by machine on 9 November 2026.
Where in China
- The Third Affiliated Hospital of Guangzhou Medical UniversityGuangzhou, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- The Third Affiliated Hospital of Guangzhou Medical University
- Trial code
- NCT06420427
- Record updated
- 20 May 2024
- Original description
Assess the sensitivity, specificity, positive predictive value, and negative predictive value of dynamic monitoring of circulating tumor DNA (ctDNA) combined with circulating HPV DNA (cfHPV DNA) for early prediction of recurrence in cervical cancer post-surgery or post-treatment, and compare its advantages and disadvantages with existing diagnostic methods.Read full original descriptionShow less
Dynamic Monitoring of Circulating Tumor DNA (ctDNA) and HPV DNA in Plasma for the Early Prediction of Recurrence After Cervical Cancer Surgery/Treatment
Assess the sensitivity, specificity, positive predictive value, and negative predictive value of dynamic monitoring of circulating tumor DNA (ctDNA) combined with circulating HPV DNA (cfHPV DNA) for early prediction of recurrence in cervical cancer post-surgery or post-treatment, and compare its advantages and disadvantages with existing diagnostic methods.
Inclusion: Patients with newly diagnosed HPV-positive cervical malignancy at stages I-IV who have not undergone surgery, radiation therapy, or chemotherapy; Patients must be older than 18 years of age; Cervical cancer patients who are eligible for surgery and/or chemoradiotherapy; Estimated life expectancy of more than three months; Understands the study protocol and voluntarily participates in the research by signing the informed consent form; Able to provide specimens and corresponding clinical information at each time point.
Exclusion: Patients with severe mental illness; Patients who are participating in other clinical trials; Pregnant or breastfeeding women; Patients who voluntarily withdraw; Patients unable to complete the study protocol.